Pharma and Biotech Daily: Top Stories in the Industry from Zenas to Lilly

Podcast: Pharma and BioTech Daily
Host: Pharma and BioTech News
Date: October 9, 2025

Episode Overview

This episode delivers a concise roundup of the day’s most impactful news stories in the pharma and biotech sectors. Highlighted topics include significant partnerships and acquisitions, leadership changes, groundbreaking research updates, and industry-wide trends. From Zenas Pharma’s $2 billion investment to Eli Lilly’s high-profile hiring of former FDA director Peter Marks, the episode reveals how major shifts are shaping the future of biotechnology and pharmaceuticals.

Key Discussion Points and Insights

1. Zenas and InnoCare’s $2 Billion Bet on Autoimmune Disease

• Summary:
  Zenas makes a landmark investment in collaboration with Chinese firm InnoCare to develop orellobrutinib for multiple sclerosis, spotlighting the growing cross-border partnerships in targeting autoimmune conditions.
• Memorable Quote:
  "[00:10] Xenos has made a $2 billion bet on autoimmune diseases with Chinese firm InnoCare focusing on the development of orellobrutinib for multiple sclerosis." (Host)

2. Leadership Shifts: Peter Marks Joins Eli Lilly

• Summary:
  Former FDA director Peter Marks takes on a senior leadership role at Eli Lilly, marking another instance of regulatory expertise moving to industry, as Lilly expands its focus in China and infectious diseases.
• Memorable Quote:
  "[00:20] Former FDA director Peter Marks has joined Eli Lilly, marking the company's continued push in China." (Host) "[01:05] Peter Marks, former director of the FDA's center for Biologics Evaluation and Research, has taken on a new role as senior vice president for mole discovery in the head of infectious diseases at Eli Lilly. Marks controversial exit from the FDA led to his hiring by Lilly." (Host)

3. Sanofi and Radiopharma

• Summary:
  Sanofi makes notable advancements in radiopharmaceuticals, a key focus area for therapeutic innovation.
• Memorable Quote:
  "[00:25] Sanofi's advancements in radiopharma..." (Host)

4. Boehringer Ingelheim Breakthrough in IPF

• Summary:
  Boehringer Ingelheim achieves a breakthrough in the challenging field of idiopathic pulmonary fibrosis (IPF).

5. Takeda Exits Cell Therapy

• Summary:
  Takeda’s strategic decision to exit cell therapy after building a sizable portfolio is explored, reflecting shifting company priorities.
• Memorable Quote:
  "[00:35] Takeda's exit from cell therapy are also top stories." (Host) "[00:55] Takeda's journey in building a cell therapy portfolio, only to ultimately walk away, is explored." (Host)

6. Saitiva Filtration Solution

• Summary:
  Saitiva filtration is highlighted as an essential technology for maintaining product integrity in the biopharma sector.

7. BioSpace Spotlights Women Leaders and “40 Under 40”

• Summary:
  BioSpace celebrates female leadership in smaller biotech firms and recognizes the current “40 under 40” who are making an industry impact.
• Memorable Quote:
  "[00:45] BioSpace profiles the five most powerful women leading smaller biopharmaceutical companies." (Host) "[01:00] BioSpace also honors 40 under 40 winners making an impact in the industry." (Host)

8. Industry Trends: GSK’s CEO Departure and Manufacturing

• Summary:
  Emma Walmsley’s departure signals ongoing change at the top of Big Pharma. Meanwhile, a CRB survey reveals hesitancy for new investments under current tariff conditions.
• Memorable Quote:
  "[00:50] As the industry sees a shift with the departure of GSK CEO Emma Walmsley, a survey by CRB reveals that most life sciences companies are not planning new investments after tariffs." (Host)

9. Drug Pricing Debate

• Summary:
  The conversation touches on the evolving nature of drug pricing and its oversight, especially as Big Pharma leads new manufacturing initiatives.
• Memorable Quote:
  "[00:55] Drug pricing criticism often overlooks the dynamic nature of drug pricing over time." (Host)

10. Major Transactions: Pfizer, Amgen, Roche

• Summary:
  • Pfizer wins the bid for Metsira, strengthening its specialty portfolio.
  • Amgen offers Repatha at a discounted rate, likely a response to increasing drug price scrutiny.
  • Roche acquires Akiro for $3.5 billion, showing commitment to building pipeline strength.

Notable Quotes & Memorable Moments

• [00:10] “Xenos has made a $2 billion bet on autoimmune diseases with Chinese firm InnoCare focusing on the development of orellobrutinib for multiple sclerosis.” (Host)
• [00:20] “Former FDA director Peter Marks has joined Eli Lilly, marking the company's continued push in China.” (Host)
• [00:45] “BioSpace profiles the five most powerful women leading smaller biopharmaceutical companies.” (Host)
• [01:00] “BioSpace also honors 40 under 40 winners making an impact in the industry.” (Host)
• [01:05] “Peter Marks, former director of the FDA's center for Biologics Evaluation and Research, has taken on a new role as senior vice president for mole discovery in the head of infectious diseases at Eli Lilly. Marks controversial exit from the FDA led to his hiring by Lilly.” (Host)

Timestamps for Key Segments

• 00:10 — Zenas/InnoCare $2B autoimmune deal
• 00:20 — Peter Marks joins Eli Lilly
• 00:25 — Sanofi’s radiopharma advances
• 00:30 — Boehringer Ingelheim in IPF
• 00:35 — Takeda exits cell therapy
• 00:45 — BioSpace women leaders spotlight
• 00:50 — GSK CEO departure and CRB survey
• 00:55 — Takeda’s cell therapy exit & drug pricing dynamics
• 01:00 — BioSpace 40 under 40 honors
• 01:05 — Peter Marks’ new role at Lilly

Conclusion

In this fast-paced episode, Pharma and Biotech Daily provides critical updates shaping the global pharma landscape—from eye-catching deals and leadership transitions to broad industry shifts. For listeners, this roundup delivers the strategic headlines and context needed to stay informed in biotech and pharma’s dynamic environment.